Description:

see http://clinicaltrials.gov/ct2/show/study/NCT00048295 ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant role in the increase of inflammation. People with Crohn’s disease have been shown to over-produce ICAM-1 in their gut tissues. Alicaforsen works by blocking ICAM-1 messenger RNA, the “instruction” molecule that is required for the production of ICAM-1 protein. This trial will examine effects of alicaforsen delivered by 2-hour intravenous infusion over a four-week period, compared to a placebo. Patients may remain on stable background 5-ASA, antibiotic, or immunosuppressive drugs, and prednisone (or equivalent) at </= 30 mg per day.

Link:

http://clinicaltrials.gov/ct2/show/study/NCT00048295

  1. 11/14/11 11/14/11 -
  2. 11/14/11 11/14/11 -
  3. 3/22/14 3/22/14 - Martin Dugas
  4. 9/17/21 9/17/21 -
Uploaded on:

September 17, 2021

DOI:
To request one please log in.
License :
Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00048295 Crohns Disease

Eligibility NCT00048295

  1. StudyEvent: Eligibility
    1. Eligibility NCT00048295
Inclusion
[years]
Weight at least 36 kg
CDAI score of 220 - 400
Documentation of Crohns disease activity by endoscopy, biopsy or imaging in the last 2 years
No TNF-alpha inhibitor treatment for three months prior to first study drug infusion
Exclusion
Known severe, fixed, symptomatic stenosis of the small or large intestine with significant dilation
Extensive external fistulization (> 3 external fistulae which are expressible with gentle compression); colostomy or ileostomy
Active infection, including infectious colitis, or infection with HIV, Hepatitis B or Hepatitis C
Malignancy within 3 years or poorly controlled medical illness
Requires intravenous heparin therapy or with a history of a bleeding problem

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial